Top-Rated StocksTop-RatedNASDAQ:CABA Cabaletta Bio (CABA) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free CABA Stock Alerts $17.98 -0.76 (-4.06%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$17.20▼$19.0650-Day Range$17.98▼$25.3852-Week Range$6.94▼$26.35Volume1.33 million shsAverage Volume898,493 shsMarket Capitalization$770.44 millionP/E RatioN/ADividend YieldN/APrice Target$31.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cabaletta Bio alerts: Email Address Cabaletta Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside73.5% Upside$31.20 Price TargetShort InterestBearish16.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 4 Articles This WeekInsider TradingSelling Shares$456,280 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.59) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.45 out of 5 starsMedical Sector760th out of 947 stocksBiological Products, Except Diagnostic Industry134th out of 160 stocks 3.5 Analyst's Opinion Consensus RatingCabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.20, Cabaletta Bio has a forecasted upside of 73.5% from its current price of $17.98.Amount of Analyst CoverageCabaletta Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.36% of the outstanding shares of Cabaletta Bio have been sold short.Short Interest Ratio / Days to CoverCabaletta Bio has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Cabaletta Bio has recently increased by 2.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCabaletta Bio does not currently pay a dividend.Dividend GrowthCabaletta Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CABA. Previous Next 3.2 News and Social Media Coverage News SentimentCabaletta Bio has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cabaletta Bio this week, compared to 2 articles on an average week.Search InterestOnly 23 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat Follows16 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cabaletta Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $456,280.00 in company stock.Percentage Held by Insiders12.33% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cabaletta Bio are expected to decrease in the coming year, from ($1.59) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cabaletta Bio is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cabaletta Bio is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCabaletta Bio has a P/B Ratio of 4.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Cabaletta Bio Stock (NASDAQ:CABA)Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More CABA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CABA Stock News HeadlinesMarch 19, 2024 | msn.comA major cog in Philly biotech is in congressional crosshairs for its Chinese ownershipMarch 5, 2024 | msn.comCabaletta Bio Set to Ignite Conversation at Upcoming Health Care ConferencesMarch 19, 2024 | Porter & Company (Ad)The world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.February 27, 2024 | finance.yahoo.comSeveral Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4February 27, 2024 | globenewswire.comCabaletta Bio to Participate in Upcoming Investor Conferences in MarchFebruary 21, 2024 | benzinga.comCabaletta Bio Stock (NASDAQ:CABA) Dividends: History, Yield and DatesFebruary 17, 2024 | finance.yahoo.comCABA Mar 2024 35.000 callFebruary 17, 2024 | finance.yahoo.comCABA Mar 2024 30.000 callMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 5, 2024 | markets.businessinsider.comStrong Buy Rating for Cabaletta Bio Amid Positive CART Therapy Prospects and Market PotentialFebruary 3, 2024 | msn.comFDA Awards Orphan Drug Designation to Cabaletta's Innovative Myositis TherapyFebruary 2, 2024 | msn.comCabaletta Bio CEO to Speak at Guggenheim's 6th Annual Biotech ConferenceFebruary 1, 2024 | marketwatch.comCabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease TreatmentJanuary 31, 2024 | seekingalpha.comCabaletta Bio: Two Differentiated CAR-T Platforms To Carry It ForwardJanuary 31, 2024 | finance.yahoo.comCabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 9, 2024 | finance.yahoo.comAre Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%?January 8, 2024 | msn.comCabaletta Bio gains on FDA fast-track tags for lead assetJanuary 8, 2024 | finance.yahoo.comCabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic SclerosisJanuary 2, 2024 | finance.yahoo.comCabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 20, 2023 | morningstar.comCabaletta Bio Inc Ordinary SharesDecember 19, 2023 | finance.yahoo.comCabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive RallyDecember 16, 2023 | msn.comCabaletta Bio (CABA) Price Target Increased by 5.57% to 31.77December 11, 2023 | seekingalpha.comCabaletta Bio: Expanding The Success Of CAR-T Beyond OncologyDecember 10, 2023 | seekingalpha.comBuy Cabaletta Bio's Promising SLE TreatmentNovember 28, 2023 | uk.finance.yahoo.comCabaletta Bio, Inc. (CABA)November 28, 2023 | marketwatch.comCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNovember 28, 2023 | msn.comCabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapySee More Headlines Receive CABA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2021Today3/19/2024Next Earnings (Estimated)3/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CABA CUSIPN/A CIK1759138 Webwww.cabalettabio.com Phone267-759-3100FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Stock Price Target$31.20 High Stock Price Target$50.00 Low Stock Price Target$12.00 Potential Upside/Downside+73.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.05% Return on Assets-43.21% Debt Debt-to-Equity RatioN/A Current Ratio15.65 Quick Ratio15.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.60 per share Price / Book4.99Miscellaneous Outstanding Shares42,850,000Free Float37,566,000Market Cap$770.44 million OptionableOptionable Beta2.46 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Steven A. Nichtberger M.D. (Age 63)Co-Founder, Chairman, CEO & President Comp: $970.6kDr. Gwendolyn K. Binder Ph.D. (Age 49)President of Science & Technology Comp: $692.99kDr. David J. Chang FACR (Age 61)M.D., M.P.H., Chief Medical Officer Comp: $676.74kDr. Michael C. Milone M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardDr. Aimee Payne M.D.Ph.D., Co-Founder & Co-Chair of Scientific Advisory BoardMr. Anup Marda M.B.A. (Age 47)Chief Financial Officer Comp: $548.2kDr. Samik Basu M.D.Chief Scientific OfficerMr. Michael Gerard J.D. (Age 44)General Counsel & Secretary Ms. Heather Harte-Hall M.Sc.Chief Compliance OfficerMs. Martha O'ConnorChief Human Resources OfficerMore ExecutivesKey CompetitorsHilleVaxNASDAQ:HLVXPrime MedicineNYSE:PRMETourmaline BioNASDAQ:TRMLAllogene TherapeuticsNASDAQ:ALLOREGENXBIONASDAQ:RGNXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 163,823 shares on 3/11/2024Ownership: 4.975%Wellington Management Group LLPBought 293,306 shares on 3/5/2024Ownership: 1.260%Perceptive Advisors LLCBought 870,567 shares on 2/26/2024Ownership: 4.675%Price T Rowe Associates Inc. MDBought 512,450 shares on 2/16/2024Ownership: 1.232%Citadel Advisors LLCSold 2,200 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CABA Stock Analysis - Frequently Asked Questions Should I buy or sell Cabaletta Bio stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks. What is Cabaletta Bio's stock price target for 2024? 10 brokerages have issued 12-month price objectives for Cabaletta Bio's shares. Their CABA share price targets range from $12.00 to $50.00. On average, they predict the company's stock price to reach $31.20 in the next twelve months. This suggests a possible upside of 73.5% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts. How have CABA shares performed in 2024? Cabaletta Bio's stock was trading at $22.70 at the beginning of the year. Since then, CABA shares have decreased by 20.8% and is now trading at $17.98. View the best growth stocks for 2024 here. When is Cabaletta Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our CABA earnings forecast. How were Cabaletta Bio's earnings last quarter? Cabaletta Bio, Inc. (NASDAQ:CABA) released its earnings results on Sunday, October, 31st. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.05. What ETFs hold Cabaletta Bio's stock? ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Cabaletta Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE). When did Cabaletta Bio IPO? (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO. Who are Cabaletta Bio's major shareholders? Cabaletta Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.98%), Vanguard Group Inc. (4.98%), Perceptive Advisors LLC (4.67%), Commodore Capital LP (4.43%), Jennison Associates LLC (3.80%) and Wellington Management Group LLP (1.26%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am. View institutional ownership trends. How do I buy shares of Cabaletta Bio? Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CABA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.